Patients taking the drug nearly doubled their survival time, with fewer severe side effects.

One expert told Newsweek the new approach is a "transformative shift" for patients.

Ziihera (zanidatamab-hrii) is a neoadjuvant therapy that originally received FDA approval for HER2+ cholagiocarcinoma or biliary tract cancer on November 20, 2024. The lyophilized powder is ...

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has ...

When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for ...

The Food and Drug Administration on Friday approved a new, targeted breast cancer drug for patients who become resistant to hormone therapy.

NEW HAVEN, Conn. (WTNH) — The Food and Drug Administration (FDA) recently approved a breakthrough drug for pancreatic cancer patients in the form of a daily pill. The drug was designed for patients ...

Mississippi awarded more than $104 million in federal rural health grants across 167 projects. Where the money goes and why rural access matters. Rural Virginia Paramedics Make Home Visits to Cut ...

Since the passage of the 21st Century Cures Act in 2016, Food and Drug Administration (FDA) approvals for new medical products have relied on fewer studies, according to a study published Aug. 26, ...